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Background: Osteopenia and bone loss are major complications after renal transplantation. Clinical data in
the Asian population are lacking.
Methods: We prospectively studied the changes in bone mineral density (BMD) of 31 cadaveric renal allograft
recipients using dual energy X-ray absorptiometry (DEXA) within 2 weeks after transplantation and then at 1
year post transplantation.
Results: One year after transplantation, the mean bone mineral reduction at the lumbar spine was 6.3 ± 4.9%
(osteopenia in 32.2% of patients and osteoporosis in 6.5%). For the femoral neck, there was a 4.3 ± 5.5%
decrease in BMD (osteopenia in 38.7% of patients and osteoporosis in 3.2%). For total hip, there was a 4.8 ±
3.6% decrease in BMD (osteopenia in 25.8% of patients and osteoporosis in 3.2%). Decrease in BMD at the
femoral neck and total hip correlated with the cumulative dosage of steroid (femoral neck: r = –0.36, p = 0.048;
total hip: r = –0.4, p = 0.026). Compared with patients without rejection, patients with a history of acute
rejection received higher cumulative doses of steroid, and sustained a greater decrease in BMD at the femoral
neck and total hip: median percentage (interquartile range) decrease in femoral neck BMD was 7.7% (–12.8 to
–6.3) versus 4.4% (–6.5 to –0.065), p = 0.016; decrease in total hip BMD was 8.2% (–11.22 to –6.7) versus
3.4% (–6.92 to –1.4), p = 0.03. There was no correlation between BMD changes and cumulative dosage of
cyclosporine A, azathioprine, tacrolimus, duration of dialysis, changes in body mass index, creatinine or
parathyroid hormone levels.
Conclusion: Reduction of BMD after renal transplantation is common. The cumulative dosage of prednisolone
correlates with bone loss at the femoral neck and total hip. Patients with a history of acute rejection suffered
from more bone loss after 1 year compared to patients without rejection. [Hong Kong J Nephrol 2005;7(2):
70–6]
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INTRODUCTION
Renal osteodystrophy is a common complication of
chronic renal failure. It is associated with disturbances
in calcium and phosphate metabolism, abnormal
calcium regulating hormone levels and changes in bone
structure and metabolism.
Renal transplantation has become an established
therapy for end-stage renal disease; it corrects the
disturbances in calcium and phosphate metabolism.
The restoration of vitamin D synthesis, clearance of
phosphate, and reduction of parathyroid hormone
are all beneficial to the bone after transplantation.
On the contrary, immobilization in the immediate
postoperative period and use of immunosuppressive
agents pose deleterious effects on bone mass.
Post-transplantation osteopenia or osteoporosis
remains an important problem. Studies have
demonstrated a rapid and significant rate of bone loss
within the first postoperative year [1–3]. It is thought
that bone loss after transplantation is primarily related
to glucocorticoids. Glucocorticoids decrease absorp-
tion of calcium from the intestine and increase its
elimination via the kidneys. They affect parathyroid
hormone (PTH) secretion, change the bone–protein
matrix, increase osteoclastic activity and decrease bone
formation, leading to an overall reduction in bone mass.
Use of cyclosporine A (CsA) and tacrolimus
permits lower glucocorticoid dosages. However, they
do not retard bone loss. While some studies have shown
an association between high-turnover osteoporosis
and CsA, others have not [4,5]. Both CsA and
tacrolimus have specific adverse effects on skeletal
integrity. Their independent and interrelated skeletal
effects with glucocorticoids lead to a form of bone
disease characterized by rapid bone loss and high
fracture rate.
The pathogenesis of post-transplantation
osteoporosis is complex. The impact on the skeleton
is a continuous process both before and after
transplantation. Clinical information on post-transplant
bone loss in the Chinese population is limited. We
prospectively studied the changes in bone mineral
density (BMD) in 31 cadaveric renal graft recipients.
BMD was measured by dual energy X-ray absorptio-
metry (DEXA) within 2 weeks after transplantation and
then at 1 year post-transplantation.
METHODS
Patients
Between December 2001 and January 2003, a total of
34 patients received cadaveric renal transplantation in
Queen Elizabeth Hospital. Three patients were excluded
from this study for the following reasons: age below
18 years in one, one emigrated, and one defaulted the
second set of DEXA scans. The first set of DEXA scans
was done within 2 weeks of operation and the second
set at 1 year after transplantation.
Immunosuppressive regimen
All patients received the standard triple immuno-
suppressive therapy, including steroid, azathioprine
and calcineurin inhibitor – tacrolimus or CsA. An
interleukin-2 receptor antagonist (either daclizumab or
basiliximab) and intravenous methylprednisolone (1 g)
were used as induction therapy. This was followed by
oral prednisolone 30 mg/day, which was tapered down
gradually after 1 month. Seventeen patients received
tacrolimus and 14 patients took CsA as maintenance
therapy. Azathioprine was started in all patients, but
only 22 patients were still on it at study end. It was
stopped because of deranged liver function or allergy
to azathioprine. Histologically-proven rejections were
treated with intravenous pulse methylprednisolone
0.5 g for 3–5 days. Cumulative dosages of prednisolone,
CsA, azathioprine and tacrolimus, from the date of
transplantation to the time of BMD evaluation by the
second set of DEXA scans, were calculated.
Laboratory measurements
Serum calcium, phosphate, creatinine and alkaline
phosphatase were measured before transplantation,
and then at 6 and 12 months post-transplant. Serum
PTH concentration was measured before transplanta-
tion and 1 year after transplantation.
Bone densitometry
BMD of the lumbar spine (L1–4), femoral neck and
total hip were measured by DEXA (model DPX-L;
Lunar Corp, Madison, WI, USA). The coefficient of
variation at these sites ranged from 1.5% to 2.4%.
T scores were obtained by comparing the BMD of
patients to the peak BMD of young normal individuals
from an Asian population. The normative reference data
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Table 1. Biochemical parameters before transplantation, and at 6 and 12 months after renal transplantation
Pre-transplantation
Post-transplantation
6 months 12 months
Creatinine (μmol/L) 1,024 ± 269.7 160.2 ± 32.1* 156.2 ± 43.5*†
Calcium (mmol/L) 2.43 ± 0.27 12.64 ± 0.19* †2.63 ± 0.23*
Phosphate (mmol/L) 2.05 ± 0.56 11.10 ± 0.17* 11.16 ± 0.20*†
ALP (IU/L) 91.1 ± 60.6 126.5 ± 82* 1 †118.9 ± 66.3*1
PTH (pmol/L) 49.33 ± 46.69 †14.91 ± 15.83*
*p < 0.05 vs pre-transplantation values; †p < 0.05 vs values at 6 months. ALP = alkaline phosphatase; PTH = parathyroid hormone.
were built in to the computer software of the machine.
It was based on Japanese data taken by Hamamatsu
University according to the U.S. Food and Drug
Administration guidelines and protocols (personal
communication with Lunar Corp Asia & Pacific, Tokyo,
Japan). These data were collected from over 200
patients for each decade of patient age, and the data
have been updated from time to time since 1989.
Results are expressed in g/cm2 and as the number
of standard deviations (SD) from the mean of sex-
matched young adults (known as the T score). The
prevalence of osteopenia and osteoporosis was also
assessed according to the definition of the World Health
Organization: osteopenia was defined by a T score of
between –1 and –2.5 SD, whereas osteoporosis was
defined by a T score of less than –2.5 SD.
Statistical analysis
Paired-samples t test was used to compare interval
changes, and independent Student’s t test was used to
compare intergroup differences. Non-parametric
Mann-Whitney U test was used for non-parametric data.
Pearson’s correlation coefficient was calculated
between BMD changes and various factors. Predictors
of significance that were less than 0.1 in univariate
analysis were entered into a multiple regression model
for further analysis. Results are expressed as mean ±
SD or median ± interquartile range (IQR) where
appropriate. A p value of less than 0.05 was considered
to be significant. All statistical analyses were performed
with SPSS version 10.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
All patients (19 males, 12 females) had their first renal
transplantation and were not on steroids for at least 1
year before transplantation. They were all alive, with
functioning grafts, at study end. The causes of end-
stage renal failure were chronic glomerulonephritis in
27, hypertension in one, diabetes mellitus in one,
obstructive uropathy in one, and an unknown cause in
one. The mean age at transplantation was 39.8 ± 9.2
years for males and 41.4 ± 6.1 years for females (p =
0.398). The mean duration of dialysis prior to trans-
plantation was 4.7 ± 3.3 years; 26 patients had been on
continuous ambulatory peritoneal dialysis, and five had
been on chronic hemodialysis.
The biochemical parameters of patients are shown
in Table 1. Serum creatinine concentrations before
transplantation, and 6 and 12 months after transplan-
tation were 1,024 ± 269.7, 160.2 ± 32.1 and 156.2 ±
43.5 μmol/L, respectively. The serum phosphate
concentration fell from 2.05 ± 0.56 mmol/L before
transplantation to 1.16 ± 0.20 mmol/L 1 year after
transplantation. Stable renal function was maintained
throughout the study. Mean serum PTH concentration
decreased from 49.33 ±  46.69 pmol/L before
transplantation to 14.91 ± 15.83 pmol/L 1 year after
transplantation. On the contrary, serum calcium and
alkaline phosphatase concentrations rose 1 year after
transplantation from 2.43 ± 0.27 mmol/L to 2.63 ±
0.23 mmol/L and 91.1 ± 60.6 IU/L to 118.9 ± 66.3 IU/L,
respectively.
A summary of the BMD measurements at the
lumbar spine, femoral neck and total hip are shown in
Table 2. At the lumbar spine, the mean T score was
0.29 ± 1.54 SD, 25.8% of patients were classified as
having osteopenia and none was classified as having
osteoporosis at transplantation. By 1 year post-
transplantation, there was a mean decrease of 6.25 ±
4.9% in BMD, the mean T score was –0.33 ± 1.49 SD,
32.2% of patients had osteopenia (T score between
–1 and –2.5 SD), and 6.5% had osteoporosis (T score
< –2.5 SD). At the femoral neck, the mean T score was
–0.52 ± 1.0 SD, 32.2% of all patients had osteopenia
and 3.2% had osteoporosis at transplantation. At 1 year
post-transplantation, there was a decrease of 4.30 ±
5.45% in mean BMD in all patients, the mean T score
was –0.83 ± 0.92 SD, 38.7% of all patients had
osteopenia, and 3.2% had osteoporosis. At total hip,
the mean T score was –0.15 ± 1.1 SD, 22.6% of all
patients had osteopenia and 3.2% had osteoporosis at
transplantation. At 1 year post-transplantation, there
was a decrease of 4.76 ± 3.61% in mean BMD in all
patients, the mean T score was –0.48 ± 1.0 SD, 25.8%
of patients had osteopenia, and 3.2% had osteoporosis.
In all patients, mean BMD and T score of the lumbar
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spine, femoral neck and total hip 1 year after trans-
plantation were statistically significantly different (p <
0.05) from values at transplantation.
Correlation studies using 12-month BMD data were
performed to find the relationship between various
immunosuppressive therapies with bone loss.
Cumulative prednisolone dosage correlated with bone
loss at the femoral neck (r = –0.36; p = 0.048) and total
hip (r = –0.4; p = 0.026) (Table 3), but not with the
lumbar spine. There was no correlation between the
cumulative dosage of tacrolimus, CsA or azathioprine
with BMD changes in the lumbar spine, femoral neck
and total hip. Nor was there any correlation between
changes in pre- and post-transplantation PTH levels,
duration on dialysis, or body mass index, and changes
in BMD.
Six patients had biopsy-proven acute rejection
during follow-up. All rejection episodes were treated
with intravenous pulse methylprednisolone 500 mg for
3–5 days. The median cumulative steroid dosage was
higher in this group: acute rejection versus no rejection,
9,801.3 mg (IQR, 8,625–10,288) versus 6,615 mg (IQR,
Table 2. Bone mineral density (BMD), T score and prevalence of osteopenia* and osteoporosis† at the lumbar spine (L1–4), femoral
neck and total hip
At transplantation 1 year post-transplantation p
Lumbar spine (L1–4)
   Mean BMD, g/cm2 1.189 ± 0.181 1.110 ± 0.176 < 0.01
   % BMD lost NA 6.25 ± 4.9
   Mean T score ± SD 0.29 ± 1.54 –0.33 ± 1.49 < 0.01
   Osteopenia, n (%) 8 (25.8) 10 (32.2)
   Osteoporosis, n (%) 0 (0) 2 (6.5)
Femoral neck
   Mean BMD, g/cm2 0.870 ± 0.136 0.829 ± 0.125 < 0.01
   % BMD lost NA 4.3 ± 5.45
   Mean T score ± SD –0.52 ± 1.0 –0.83 ± 0.92 < 0.01
   Osteopenia, n (%) 10 (32.2) 12 (38.7)
   Osteoporosis, n (%) 1 (3.2) 1 (3.2)
Total hip
   Mean BMD, g/cm2 0.925 ± 0.133 0.880 ± 0.127 < 0.01
   % BMD lost NA 4.7 ± 3.61
   Mean T score ± SD –0.15 ± 1.1 –0.48 ± 1.0 < 0.01
   Osteopenia, n (%) 7 (22.6) 8 (25.8)
   Osteoporosis, n (%) 1 (3.2) 1 (3.2)
*Osteopenia was defined by a T score of between –1 and –2.5 SD; †osteoporosis was defined by a T score < –2.5 SD.
Table 3. Correlation between changes in bone mineral density (BMD) of the lumbar spine, femoral neck and total hip, and various
parameters
Lumbar spine BMD Femoral neck BMD Total hip BMD
r p r p r p
Cumulative dosage
   Prednisolone (g) 0.083 0.65 –0.36 0.048* –0.4 0.026*
   Azathioprine (mg) –0.12 0.57 –0.019 0.93 0.143 0.49
   Cyclosporine A (mg) –0.11 0.71 0.22 0.44 0.27 0.35
   Tacrolimus (mg) –0.19 0.44 0.123 0.62 –0.183 0.45
PTH level (pmol/L)
   Pre-transplantation –0.047 0.81 –0.281 0.14 –0.31 0.101
   Post-transplantation 0.016 0.934 –0.053 0.776 –0.18 0.33
Duration on dialysis (yr) –0.295 0.108 –0.023 0.9 –0.004 0.99
Change in BMI –0.13 0.49 –0.158 0.395 –0.03 0.99
*Statistically significant at p < 0.05. BMI = body mass index; PTH = parathyroid hormone.
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6,135–7,142.5; p < 0.01). At the femoral neck, in
patients with acute rejection compared with patients
who did not have rejection, there was a greater decrease
in BMD: –0.063 g/cm2 versus –0.04 g/cm2 (p = 0.032).
There was also a greater decrease in percentage BMD
loss: –7.7% versus –4.4% (p = 0.016). There were
similar significant results at total hip, i.e. a greater
decrease in BMD (–0.0685 vs –0.032 g/cm2; p = 0.012),
and a greater decrease in percentage BMD loss
(–8.2 vs –3.4%; p = 0.03). At the lumbar spine, however,
no significant differences were observed between
patients with and without acute rejection (Table 4).With
regard to biochemical parameters, mean BMD and
T scores at the lumbar spine, femoral neck and total
hip, the differences between the two groups were not
significant (p > 0.05).
Acute rejection and steroid dosage were shown to
be significant (p < 0.1) in the univariate analysis, so
they were entered into multiple regression models for
multivariate analysis. However, neither of them reached
statistical significance.
DISCUSSION
The mean PTH level was 49.33 ± 46.69 pmol/L before
transplantation and 14.91 ± 15.83 pmol/L 1 year after
transplantation. This was due to partial resolution of
parathyroid gland hyperplasia. Complete resolution
may take several years. Some studies have found an
association between bone loss and pre-transplantation
PTH [3,6,7], but others did not [1,8,9]. In our study,
we could not find any correlation between pre or post-
transplantation PTH levels and degree of bone loss.
The mean serum calcium concentration rose from
2.43 ± 0.27 mmol/L before transplantation to 2.63 ±
0.23 mmol/L 1 year post-transplantation. Transient
hypercalcemia after renal transplantation is well
tolerated, does not cause renal dysfunction, and
generally resolves within a year [10]. Hypercalcemia
appeared to be due to incomplete resolution of
parathyroid hyperplasia despite a drop in serum PTH.
Bone-specific alkaline phosphatase is a marker of
osteoblastic activity. A decrease in plasma alkaline
phosphatase levels indicating less bone resorption
is expected after renal transplantation. However, in
this study, alkaline phosphatase rose from 91.1 ±
60.6 IU/L at baseline to 118.9 ± 66.3 IU/L at 1 year
post-transplantation. This may reflect incomplete
resolution of hyperparathyroidism and pre-existing
renal osteodystrophy.
We observed significant reductions in BMD at the
lumbar spine, femoral neck and total hip 1 year after
transplantation, but none of our patients suffered
fractures. Julian et al documented a loss of BMD at
the lumbar spine of 8.8 ± 7.0% at 18 months post-
transplantation, with most of the bone loss occurring
in the first 6 months [1]. In other studies, a rapid decline
in BMD was observed in the first 6–18 months after
renal transplantation, ranging from 3% to 7% at the
lumbar spine, and 3% to 9% at the femoral neck [1,3,6,
8,11,12]. Our observations are comparable with those
of other studies. Whether bone loss continues after 1.5
years is a matter of some controversy. Some studies
have shown that BMD continues to decline [13,14],
while others have found that BMD stabilizes [6,8,11,
12] or even increases [15,16].
At 1 year after transplantation, we found that the
prevalence of osteopenia and osteoporosis was con-
siderable. Other cross-sectional studies reported low
bone mass after years of renal transplantation. The
highest percentages of osteoporosis at the lumbar spine
and femoral neck range from 17% to 49% and 11% to
56%, respectively [9,14,17–19]. It appears that bone loss
after transplantation is a long-term problem. Different
results from different studies reflect different patient
populations, study sizes, years of follow-up, immuno-
suppressant regimens, and use of different end points
Table 4. Bone mineral density (BMD) changes in the femoral neck, total hip and lumbar spine in patients with and without acute
rejection*
Acute rejection (n = 6) No rejection (n = 25) p
Lumbar spine
   Change in BMD, g/cm2 –0.065 (–0.086 to –0.052) –0.063 (–0.13 to –0.03) 0.88
   % change in BMD –6.14 (–7.5 to –3.9)11 1   –5.6 (–10.4 to –2.9) 0.88
Femoral neck
   Change in BMD, g/cm2 –0.063 (–0.127 to –0.045)     –0.04 (–0.54 to –0.065) 0.032
   % change in BMD –7.7 (–12.8 to –6.3) 1  –4.4 (–6.5 to –0.9). 0.016
Total hip
   Change in BMD, g/cm2 –0.0685 (–0.114 to –0.059)      –0.032 (–0.0675 to –0.014) 0.012
   % change in BMD  1–8.2 (–11.2 2 to –6.7)  –3.4 (–6.92 to –1.4) 0.03
*Data are presented as median (interquartile range).
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such as T score or Z score. The prevalence of osteo-
porosis was low in our patients compared with other
studies; this may be due to the short period of follow-
up (for 1 year only after transplantation). Serial DEXA
scans to measure serial changes in BMD and prevalence
of osteoporosis is needed for a longer duration.
Glucocorticoids are known to be associated with
osteoporosis. In our study, we observed a negative
correlation between cumulative dose of steroid with
change in BMD at the femoral neck and total hip. Six
patients who had biopsy-proven rejection during the
study period were given intravenous pulse methyl-
prednisolone, and they received a higher cumulative
dosage of steroid by the end of the study than the other
patients. At the femoral neck and total hip, there was a
greater decrease in BMD in the patients with acute
rejection than in those who did not have rejection.
Cumulative steroid dosage is an important factor in bone
loss after transplantation. Univariate analysis showed
that acute rejection and cumulative prednisolone dosage
correlated with BMD loss at the femoral neck and total
hip. No other factors showed significant correlation.
After multivariate analysis, however, these two
variables became insignificant. This result may be
related to the small sample size in this study and the
presence of multiple confounding factors affecting
BMD loss. Theoretically, the greater BMD loss in
patients with acute rejection could be due to the use of
steroid, other immunosuppressive drugs, or other
unknown factors.
No correlation between lumbar spine bone loss and
cumulative dosage of glucocorticoids could be found.
The density of all mineral components encountered by
the X-ray beam, including osteophytes, vascular and
extra vertebral calcifications, may be taken into the
measurement of BMD [20]. We took X-rays of the
lumbar spine for all the patients in this study: 13 had
degenerative changes but no fracture or collapse was
seen. Degenerative changes can falsely increase the
bone mass measured by DEXA scan in the lumbar
region, i.e. there might actually be more bone loss in
the lumbar region than measured. This may explain
why we failed to demonstrate any correlation between
BMD changes and steroid dosage. There was no arti-
fact documented in X-rays of the hip.
There are conflicting results in the literature relating
to the effects of CsA on bone mass. Most evidence
shows that CsA induces bone loss in rats. However, its
effects in humans remain unclear. Some studies related
low BMD to CsA dosage [7,9], but most studies did
not demonstrate any toxic effects of CsA on bone [1,3,
11,12,16]. Tacrolimus has similar actions as CsA, so
its osteotoxic effect is expected to be similar. In the
rat skeleton, it causes bone loss to an even greater
magnitude than CsA [21]. No adverse effect of
azathioprine on bone mass has been reported. We did
not find any correlation between the cumulative dosages
of CsA, tacrolimus or azathioprine with changes in
BMD.
None of our patients had received prophylactic anti-
osteoporosis therapy after transplantation. Bis-
phosphonates are successful in preventing bone loss
after transplantation. Repeated doses of intravenous
pamidronate in heart [22], lung [23] and renal transplant
recipients [24] have been shown to prevent bone loss
at the lumbar spine and femoral neck. A major limitation
of these studies, however, is the relatively small number
of patients. None of the studies were able to determine
the direct relationship between improvement in clinical
outcome (i.e. fracture rate) with improvement in BMD.
There is a high prevalence of low turnover or adynamic
bone disease in renal transplant recipients [25].
Pamidronate treatment inhibits bone resorption and
exacerbates adynamic bone disease [26]. The
significance of adynamic bone with improved BMD in
long-term bone health in renal transplant recipients
requires further study. Bisphosphonates are excreted
via the kidneys and are not recommended in patients
with moderate to severe renal insufficiency; they have
been implicated in the development of collapsing focal
glomerulosclerosis [27]. Vitamin D and calcitonin
supplements have been used for treatment of
glucocorticoid-induced osteoporosis. Talalaj et al found
that vitamin D and calcium supplements increased
BMD in post-transplant patients. In untreated patients,
BMD decreased by 7% at the lumbar spine and 6% at
the femoral neck after 1 year [28]. One study showed
that calcitonin was effective in the treatment of liver
transplant recipients [29]. However, its effectiveness
in preventing bone loss in renal transplant patients is
not well documented [30]. It is probably not more
effective than bisphosphonates. Anti-resorptive therapy
to reduce fractures cannot be recommended as standard
therapy at present as no studies have demonstrated a
reduction in fracture rate with treatment.
This study has several limitations. First, the sta-
tistical power is low, as only 31 patients were studied.
Osteoporosis is a skeletal disorder characterized by
compromised bone strength, which predisposes to
increased risk of fracture. Bone strength is determined
by bone density and quality. DEXA only measures bone
density, and factors of bone quality such as architecture,
turnover and mineralization were not measured. BMD
correlates with bone histology poorly and has no role
in the assessment of bone turnover. The measurement
of BMD alone, without documenting bone quality, may
have limited the diagnostic meaning in renal patients
[31]. The role of BMD in predicting individual fracture
risk in the post renal transplantation population remains
uncertain. Data from clinical trials suggest that
bisphosphonates are the most promising agents for the
prevention and treatment of osteoporosis. Although
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their benefit on BMD has been documented by various
studies, the efficacy of anti-resorptive therapy in
reducing fracture rate is not clear. In this study, we
observed bone loss in our patients 1 year after
transplantation, but whether or not bone loss contin-
ues after 1 year is not known. Extended follow-up is
required to show the trend in BMD changes in our
cohort. Multicenter studies involving larger patient
numbers are needed to clarify the relationship between
BMD changes and fracture prevalence.
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